Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Stock Short Interest Drops 95.6%

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) saw a large decline in short interest during the month of September. As of September 30th, there was short interest totaling 19,900 shares, a decline of 95.6% from the September 15th total of 451,633 shares. Currently, 7.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,643,901 shares, the days-to-cover ratio is presently 0.0 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded shares of Scinai Immunotherapeutics from a “sell (e+)” rating to a “sell (e)” rating in a research note on Tuesday. One investment analyst has rated the stock with a Sell rating. According to MarketBeat, the stock presently has an average rating of “Sell”.

Scinai Immunotherapeutics Price Performance

NASDAQ:SCNI traded down $0.03 during mid-day trading on Friday, reaching $1.18. 19,238 shares of the company’s stock traded hands, compared to its average volume of 3,262,237. Scinai Immunotherapeutics has a 12-month low of $1.06 and a 12-month high of $15.65. The company has a quick ratio of 1.35, a current ratio of 1.56 and a debt-to-equity ratio of 0.05. The company has a 50 day moving average price of $2.06 and a 200-day moving average price of $3.57.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. is an Israel-based clinical-stage biopharmaceutical company focused on developing immunotherapies for inflammatory and autoimmune diseases. The company’s research centers on NanoAb, its proprietary platform of single-domain antibodies designed to target disease-related proteins and potentially support localized treatment with reduced systemic exposure.

Scinai’s lead development program is SCNI-153, a NanoAb-based candidate targeting interleukin-17 (IL-17) for the treatment of plaque psoriasis.